Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

New therapies such as immune checkpoint blockers (ICB) have offered extended survival to patients affected by advanced melanoma. However, ICBs have demonstrated debilitating side effects on the joints, liver, lungs, skin, and gut. Several biomarkers have been identified for their role in predicting which patients better tolerate ICBs. Still, these biomarkers are limited by immunologic and genetic heterogeneity and the complexity of translation into clinical practice. Recent observational studies have suggested eosinophil counts, and serum levels of eosinophil cationic protein are significantly associated with prolonged survival in advanced-stage melanoma. It is likely that eosinophils thereby modulate treatment response through mechanisms yet to be explored. Here, we review the functionality of eosinophils, their oncogenic role in melanoma and discuss how these mechanisms may influence patient response to ICBs and their implications in clinical practice. © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


India Robinson, Gabriella Santa Lucia, Andraia Li, Nathaniel Oberholtzer, John Plante, Kristen M Quinn, Daniel Reuben, Shikhar Mehrotra, Manuel Valdebran. Eosinophils and melanoma: Implications for immunotherapy. Pigment cell & melanoma research. 2022 Mar;35(2):192-202

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 34927354

View Full Text